أعضاء هيئة التدريس - جامعة بنها
Short Term Outcome Of Rosuvastatin Versus High Dose Atorvastatin In Patients With Acute Coronary Syndrome
• 2018
معلومات البحث
المؤلفون
Marwa K.Mahmoud 1(M.Sc), Khaled E. El-rabat1(MD), Shima A. Mostafa1(MD), Mohamed M. Ali 1(MD)
الكلمات المفتاحية
Not Available
المجلة العلمية
Not Available
الناشر
Not Available
المجلد
Not Available
العدد
Not Available
الصفحات
Not Available
publication.type
International
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
Abstract
Inspite of guidelines recommendations about reduction of lipid profile parameters to decrease recurrent cardiovascular events and improving outcome. Decision to choose which drug to achieve target levels is still under study .so our study aiming to assess safety and efficacy of Rosuvastatin 40mg and Atrovastatin 80mg in patients with acute coronary syndrome.
.
Methods: one hundred patients divided into two equal groups randomized for two drugs and followed up at 1 month and 3 months from the date of admission. and Routine lab tests on admission including (LFT,KFT,CBC,coagulation profile,lipid profile). Follow up after one month of admission including anti-inflammatory markers(ESR,hs-CRP,TLC). follow up after three months of admission including lipid profile(LDL-C,HDL-C,TC,TG),echo parameters and clinical outcome.
.
Results: at baseline there was no significant difference in age, gender, risk factors, lipid profile and inflammatory markers between 2 groups p>0.05. After 3 months HDL increased from 38.7±13.3to 45.6±13.3vs 36.4±9.5 to 35.3±9.4 in groups A and B respectively, P
Inspite of guidelines recommendations about reduction of lipid profile parameters to decrease recurrent cardiovascular events and improving outcome. Decision to choose which drug to achieve target levels is still under study .so our study aiming to assess safety and efficacy of Rosuvastatin 40mg and Atrovastatin 80mg in patients with acute coronary syndrome.
.
Methods: one hundred patients divided into two equal groups randomized for two drugs and followed up at 1 month and 3 months from the date of admission. and Routine lab tests on admission including (LFT,KFT,CBC,coagulation profile,lipid profile). Follow up after one month of admission including anti-inflammatory markers(ESR,hs-CRP,TLC). follow up after three months of admission including lipid profile(LDL-C,HDL-C,TC,TG),echo parameters and clinical outcome.
.
Results: at baseline there was no significant difference in age, gender, risk factors, lipid profile and inflammatory markers between 2 groups p>0.05. After 3 months HDL increased from 38.7±13.3to 45.6±13.3vs 36.4±9.5 to 35.3±9.4 in groups A and B respectively, P